0
Skip to Content
Lanton Law
Home
Healthcare & Life Sciences
Pharmacy Law
Oncology & Hematology
340B Drug Pricing Program
Outside General Counsel
Technology
Business, Estate & Legacy Planning
Commercial Real Estate
International Arbitration
Employment Law
Mergers & Acquisitions
Government Affairs
Insights
Contact
Lanton Law
Home
Healthcare & Life Sciences
Pharmacy Law
Oncology & Hematology
340B Drug Pricing Program
Outside General Counsel
Technology
Business, Estate & Legacy Planning
Commercial Real Estate
International Arbitration
Employment Law
Mergers & Acquisitions
Government Affairs
Insights
Contact
Home
Folder: Healthcare & Life Sciences
Back
Healthcare & Life Sciences
Pharmacy Law
Oncology & Hematology
340B Drug Pricing Program
Outside General Counsel
Folder: Business & Legal Services
Back
Technology
Business, Estate & Legacy Planning
Commercial Real Estate
International Arbitration
Employment Law
Mergers & Acquisitions
Government Affairs
Insights
Contact
Ron Lanton 11/17/26 Ron Lanton 11/17/26

What Happens to a Biotech Licensing Agreement When the FDA Says No?

An FDA regulatory setback can affect milestone payments, development costs and commercialization obligations. Biotechnology executives should understand how licensing agreements allocate these risks.

Read More

Our Locations

Boston
Washington, D.C.

Explore

Healthcare & Life Sciences
Employment Law
International Arbitration
Insights
Contact

Lanton, Lanton & Sosa Law, PLLC

2001 L Street, Suite 500
Washington, D.C. 20036

rlanton@lantonlaw.com
(240) 482-6060